| Schedule of Single Reportable Segment Profit or Loss Information |
The Company's single reportable segment profit or loss information is as follows:
|
|
|
|
|
|
|
|
|
|
|
Years Ended
December 31, |
|
|
|
2025 |
|
|
2024 |
|
|
|
(In thousands) |
|
Laboratory Services |
|
$ |
4,031 |
|
|
$ |
1,859 |
|
Laboratory Developed Test Services |
|
|
— |
|
|
|
22 |
|
Kitted Products |
|
|
24 |
|
|
|
— |
|
Total net revenues |
|
|
4,055 |
|
|
|
1,881 |
|
Less: |
|
|
|
|
|
|
Cost of revenues, as adjusted |
|
|
1,668 |
|
|
|
983 |
|
Personnel-related expenses and board fees |
|
|
12,823 |
|
|
|
11,000 |
|
Professional fees, legal, and outside services |
|
|
7,974 |
|
|
|
5,008 |
|
Facilities and insurance |
|
|
1,758 |
|
|
|
2,071 |
|
Laboratory supplies and expenses |
|
|
3,930 |
|
|
|
1,826 |
|
Marketing and advertising |
|
|
582 |
|
|
|
257 |
|
Travel and entertainment |
|
|
849 |
|
|
|
585 |
|
Other segment items (1) |
|
|
633 |
|
|
|
81 |
|
Segment loss |
|
|
(26,162 |
) |
|
|
(19,930 |
) |
Reconciliation of segment profit and loss: |
|
|
|
|
|
|
Depreciation and amortization expenses |
|
|
(2,197 |
) |
|
|
(1,564 |
) |
Stock-based compensation |
|
|
(2,219 |
) |
|
|
(1,753 |
) |
Change in fair value of contingent consideration |
|
|
(5,946 |
) |
|
|
4,275 |
|
Impairment losses |
|
|
(14,600 |
) |
|
|
(41,900 |
) |
Impairment loss on held for sale assets |
|
|
— |
|
|
|
(169 |
) |
Interest expense |
|
|
(109 |
) |
|
|
(84 |
) |
Other income, net |
|
|
1,011 |
|
|
|
462 |
|
Income taxes |
|
|
— |
|
|
|
— |
|
Net loss |
|
$ |
(50,222 |
) |
|
$ |
(60,663 |
) |
(1)Other segment items primarily includes clinical trial expenses, delivery expenses, other business taxes and tax credits, and severance costs. For the years ended December 31, 2025 and 2024, clinical trial expenses were $301,000 and $2,000, respectively.
|
| Schedule of Revenues and Long-lived Tangible Assets by Geographic Area |
The Company's revenues and long-lived tangible assets by geographic area are presented below. Revenues are based on the customer country of domicile. Assets are based on the location of held assets.
|
|
|
|
|
|
|
|
|
|
|
Years Ended
December 31, |
|
|
|
2025 |
|
|
2024 |
|
|
|
(In thousands) |
|
Revenues by geographic area: |
|
|
|
|
|
|
United States |
|
$ |
4,031 |
|
|
$ |
1,673 |
|
Europe |
|
|
24 |
|
|
|
18 |
|
United Kingdom |
|
|
— |
|
|
|
45 |
|
Asia-Pacific |
|
|
— |
|
|
|
145 |
|
Total net revenues |
|
$ |
4,055 |
|
|
$ |
1,881 |
|
|
|
|
|
|
|
|
|
|
|
|
December 31, |
|
|
|
2025 |
|
|
2024 |
|
|
|
(In thousands) |
|
Long-lived tangible assets by geographic area: |
|
|
|
|
|
|
United States |
|
$ |
7,177 |
|
|
$ |
5,543 |
|
Europe |
|
|
1,577 |
|
|
|
611 |
|
United Kingdom |
|
|
433 |
|
|
|
— |
|
Asia-Pacific |
|
|
63 |
|
|
|
170 |
|
Total |
|
$ |
9,250 |
|
|
$ |
6,324 |
|
|